Bafna Pharmaceuticals Past Earnings Performance
Past criteria checks 5/6
Bafna Pharmaceuticals has been growing earnings at an average annual rate of 62.3%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 27.8% per year. Bafna Pharmaceuticals's return on equity is 13.7%, and it has net margins of 7.3%.
Key information
62.3%
Earnings growth rate
86.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 27.8% |
| Return on equity | 13.7% |
| Net Margin | 7.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bafna Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,533 | 113 | 191 | 0 |
| 30 Sep 23 | 1,591 | 172 | 186 | 0 |
| 30 Jun 23 | 1,404 | 163 | 166 | 0 |
| 31 Mar 23 | 1,153 | 113 | 167 | 0 |
| 31 Dec 22 | 881 | 50 | 152 | 0 |
| 30 Sep 22 | 743 | 37 | 150 | 0 |
| 30 Jun 22 | 808 | 44 | 150 | 0 |
| 31 Mar 22 | 851 | 52 | 149 | 0 |
| 31 Dec 21 | 920 | 88 | 150 | 0 |
| 30 Sep 21 | 890 | 80 | 146 | 0 |
| 30 Jun 21 | 758 | 61 | 137 | 0 |
| 31 Mar 21 | 712 | 58 | 122 | 0 |
| 31 Dec 20 | 625 | 256 | 114 | 0 |
| 30 Sep 20 | 551 | 28 | 106 | 0 |
| 30 Jun 20 | 523 | 18 | 100 | 0 |
| 31 Mar 20 | 425 | -19 | 106 | 0 |
| 31 Dec 19 | 522 | -394 | 123 | 0 |
| 30 Sep 19 | 421 | -178 | 99 | 0 |
| 30 Jun 19 | 404 | -196 | 95 | 0 |
| 31 Mar 19 | 436 | -199 | 93 | 0 |
| 31 Mar 18 | 480 | -167 | 78 | 0 |
| 31 Mar 17 | 655 | -191 | 72 | 0 |
| 31 Mar 16 | 863 | -140 | 73 | 0 |
| 31 Mar 15 | 1,017 | 62 | 128 | 0 |
| 31 Mar 14 | 1,861 | 14 | 244 | 0 |
Quality Earnings: 532989 has high quality earnings.
Growing Profit Margin: 532989's current net profit margins (7.3%) are higher than last year (5.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532989 has become profitable over the past 5 years, growing earnings by 62.3% per year.
Accelerating Growth: 532989's earnings growth over the past year (127.5%) exceeds its 5-year average (62.3% per year).
Earnings vs Industry: 532989 earnings growth over the past year (127.5%) exceeded the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: 532989's Return on Equity (13.7%) is considered low.